restor3d closed a $55 million Series A funding round led by private investors, including Summers Value Partners and existing investors, plus an additional $15 million in debt financing led by Trinity Capital.
restor3d plans to introduce new patient-specific implant systems for total ankle and shoulder replacement. In its patient-specific hip and knee portfolios, the company will continue to make product advancements including a porous press-fit knee enabled by 3D printing of both the tibial and femoral components.
Continued investments in novel 3D printing technologies will expand restor3d’s in-house “powder to sterile product” production environment, providing the capacity to grow the business for many years to come. In addition to providing capacity, these investments will also shorten personalized implant delivery times while simultaneously reducing production costs.
Other endeavors will include continued investment in software, design automation and the advancement of medical education and training.
CEO Kurt Jacobus said, “With this capital, we can accelerate our efforts to transform orthopedic care through 3D-printed personalized implants. We are eager to maximize our impact on patient outcomes and continue to advance of orthopedic care. We are grateful for the support from our investors and look forward to a future of continued growth and success.”
restor3d closed a $55 million Series A funding round led by private investors, including Summers Value Partners and existing investors, plus an additional $15 million in debt financing led by Trinity Capital.
restor3d plans to introduce new patient-specific implant systems for total ankle and shoulder replacement. In its patient-specific hip...
restor3d closed a $55 million Series A funding round led by private investors, including Summers Value Partners and existing investors, plus an additional $15 million in debt financing led by Trinity Capital.
restor3d plans to introduce new patient-specific implant systems for total ankle and shoulder replacement. In its patient-specific hip and knee portfolios, the company will continue to make product advancements including a porous press-fit knee enabled by 3D printing of both the tibial and femoral components.
Continued investments in novel 3D printing technologies will expand restor3d’s in-house “powder to sterile product” production environment, providing the capacity to grow the business for many years to come. In addition to providing capacity, these investments will also shorten personalized implant delivery times while simultaneously reducing production costs.
Other endeavors will include continued investment in software, design automation and the advancement of medical education and training.
CEO Kurt Jacobus said, “With this capital, we can accelerate our efforts to transform orthopedic care through 3D-printed personalized implants. We are eager to maximize our impact on patient outcomes and continue to advance of orthopedic care. We are grateful for the support from our investors and look forward to a future of continued growth and success.”
Copy to clipboard 
